The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.
 
Dominick Bossé
No Relationships to Disclose
 
Wanling Xie
Consulting or Advisory Role - Bayer
 
Yasser Ged
No Relationships to Disclose
 
Andrew W Hahn
No Relationships to Disclose
 
Paulo Gustavo Bergerot
No Relationships to Disclose
 
Thai Huu Ho
No Relationships to Disclose
 
Rana R. McKay
Research Funding - Bayer (Inst); Pfizer (Inst)
 
Tracy Lynn Rose
Research Funding - Roche/Genentech; X4 Pharma
 
Guillermo de Velasco
Consulting or Advisory Role - Astellas Medivation; Bayer; Janssen; Novartis; Pfizer
Research Funding - Ipsen
Other Relationship - Janssen
 
Nizar M. Tannir
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Exelixis; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
 
Pheroze Tamboli
No Relationships to Disclose
 
Leonard Joseph Appleman
Research Funding - Acerta Pharma (Inst); Agensys (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); Medivation/Astellas; Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Sotio (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer; Cerulean Pharma; Exelixis
 
Kimryn Rathmell
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Incyte (I); Merck (I); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); TRACON Pharma (Inst)
 
A. Ari Hakimi
No Relationships to Disclose
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Neeraj Agarwal
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst)
 
Sabina Signoretti
No Relationships to Disclose
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Calithera Biosciences; Eisai; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche
Travel, Accommodations, Expenses - MedImmune; Takeda
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Ipsen; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)